NCT03333031: A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

NCT03333031
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: To be eligible for the expansion phase, patients must have mammographically detected breast nodules with planned surgical resection or biopsy
Exclusions: 
https://ClinicalTrials.gov/show/NCT03333031

Comments are closed.

Up ↑